Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma.
The distribution of hepatitis C virus (HCV) genotypes among Egyptian patients positive for anti-HCV was determined and their influence, when combined with neu-oncoprotein overexpression, on the development of hepatocellular carcinoma (HCC) was examined. The study groups included asymptomatic carriers (ASC) and patients with chronic active hepatitis (CAH) and HCC. HCV genomes were detected in the sera of 27 ASC, 29 CAH and 33 HCC patients known to have HCV infection defined by EIA and recombinant immunoblotting techniques (Inno-LiA) as well as by reverse transcriptase (RT)-PCR. The HCV genotype was determined by a reverse hybridisation technique (Inno-LiPA I and II), whereas neu-overexpression was detected by the Oncogene Science EIA Kit. Eighty-nine patients were eligible for HCV genotyping; 75 patients (84.3%) were infected with a single genotype, including 1a in 11 patients (12.4%), 1b in 2 patients (2.2%) and 2a in 10 patients (11.2%). Genotype 4 (a or c+d) was detected in 51 patients (57.3%) and only one patient had genotype 10a (1.2%). Fourteen patients (15.7%) showed mixed infection; eight of them had 1a+4 (a or c+d) and four had 2a+4 (a or c+d); the remaining two cases had 1a+2a and 1b+2a. The results revealed an increased incidence of genotype 4 in CAH and HCC patients in comparison with ASC. There was also a significant overexpression of neu-oncoprotein in CAH and HCC patients compared with ASC, which was significantly associated with subtype 4 infection. The results suggest that infection with subtype 1a and 4 HCV may be considered a risk factor for the induction of neu-overexpression and subsequent development of HCC.
Zekri
Abdel-Rahman N
AN
Bahnassy
Abeer A
AA
Virology and Immunology Unit, *Tissue Culture Unit, Pathology Department, †Biochemistry Unit, Cancer Biology Department, National Cancer Institute, Cairo University, ‡Tropical Medicine Department, Ain Shams University, §Medical Oncology Department, National Cancer Institute, Cairo University and ∥Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Shaarawy
Sabry M
SM
Virology and Immunology Unit, *Tissue Culture Unit, Pathology Department, †Biochemistry Unit, Cancer Biology Department, National Cancer Institute, Cairo University, ‡Tropical Medicine Department, Ain Shams University, §Medical Oncology Department, National Cancer Institute, Cairo University and ∥Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Mansour
Ossama A
OA
Virology and Immunology Unit, *Tissue Culture Unit, Pathology Department, †Biochemistry Unit, Cancer Biology Department, National Cancer Institute, Cairo University, ‡Tropical Medicine Department, Ain Shams University, §Medical Oncology Department, National Cancer Institute, Cairo University and ∥Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Maduar
Mohamed A
MA
Virology and Immunology Unit, *Tissue Culture Unit, Pathology Department, †Biochemistry Unit, Cancer Biology Department, National Cancer Institute, Cairo University, ‡Tropical Medicine Department, Ain Shams University, §Medical Oncology Department, National Cancer Institute, Cairo University and ∥Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Khaled
Hussein M
HM
Virology and Immunology Unit, *Tissue Culture Unit, Pathology Department, †Biochemistry Unit, Cancer Biology Department, National Cancer Institute, Cairo University, ‡Tropical Medicine Department, Ain Shams University, §Medical Oncology Department, National Cancer Institute, Cairo University and ∥Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
El-Ahmadi
Omer
O
Virology and Immunology Unit, *Tissue Culture Unit, Pathology Department, †Biochemistry Unit, Cancer Biology Department, National Cancer Institute, Cairo University, ‡Tropical Medicine Department, Ain Shams University, §Medical Oncology Department, National Cancer Institute, Cairo University and ∥Biochemistry Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000628:therapy / Q000821:virology*; D002353:Carrier State / Q000821:virology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D015967:Gene Expression Regulation, Viral; D018734:Genes, erbB-2; D005838:Genotype; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics; D006526:Hepatitis C / Q000150:complications / Q000821:virology*; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000150:complications / Q000821:virology; D006801:Humans; D007167:Immunotherapy; D008113:Liver Neoplasms / Q000628:therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology
D018937:Hepatitis C Antibodies; D018719:Erb-b2 Receptor Tyrosine Kinases